Premium
Validation of a hydrophilic interaction ultra‐performance liquid chromatography–tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine
Author(s) -
Mano Yuji,
Sakamaki Kenji,
Ueno Takuya,
Kita Kenji,
Ishii Takuho,
Hotta Koichiro,
Kusano Kazutomi
Publication year - 2015
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.3429
Subject(s) - chromatography , chemistry , bioanalysis , electrospray ionization , gemcitabine , reproducibility , tandem mass spectrometry , protein precipitation , selected reaction monitoring , mass spectrometry , liquid chromatography–mass spectrometry , high performance liquid chromatography , medicine , surgery , chemotherapy
A simple and reproducible bioanalytical method for the determination of gemcitabine in human plasma treated with tetrahydrouridine (THU) was developed and validated using a hydrophilic interaction ultra‐performance liquid chromatography with tandem mass spectrometry (UPLC‐MS/MS). To prevent deamination of gemcitabine, blood was treated with THU, and the plasma samples obtained after centrifugation were used in this study. Gemcitabine and gemcitabine‐ 13 C, 15 N 2 used as an internal standard, were extracted from human plasma treated with THU using a 96‐well Hybrid SPE‐Precipitation plate. Extracts were chromatographed on a hydrophilic interaction chromatography column with isocratic elution. Detection was performed using Quattro Premier with positive electrospray ionization multiple reaction monitoring mode. The standard curve ranged from 10 to 10,000 ng/mL without carryover. No significant interferences were detected in blank plasma and no interferences by 2′‐2′‐difluoro‐2′‐deoxyuridine, a metabolite of gemcitabine. Accuracy and precision in the intra‐batch reproducibility study using quality control samples with three THU levels did not exceed ±5.4 and 7.3%, respectively, and the inter‐batch reproducibility results also met the criteria. Stability of gemcitabine was ensured in whole blood and plasma as well as stability of THU in solutions. The UPLC‐MS/MS method developed was successfully validated and can be applied for gemcitabine bioanalysis in clinical studies. Copyright © 2015 John Wiley & Sons, Ltd.